Hyglos GmbH is a leading German biotech company offering products for the capture, detection and decolonization of bacteria and bacterial components based on its advanced, proprietary phage-ligand technology. It is owned by Hyglos Invest GmbH and Institut Mérieux, investors coming from science and industry. Hyglos' core competency is to exploit the principles of bacteriophage biology for diagnostic, antimicrobial and research applications relating to:

• Endotoxin detection
• Endotoxin removal
• Endotoxin-free proteins and reagents
• Food and environmental microbiology
• Human Diagnostics
• Antimicrobials (e.g. MRSA)

Hyglos GmbH, founded in 2009 as a follow company of Profos AG, currently employs 19 permanent staff, including scientists and marketing & sales specialists. The company is located in Bernried, near to Munich, one of the most important biotechnology regions in Germany.